bioAffinity Technologies, Inc.
BIAF
$0.83
-$0.01-1.23%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -35.75% | -34.18% | -27.66% | 4.99% | 78.40% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -35.75% | -34.18% | -27.66% | 4.99% | 78.40% |
| Cost of Revenue | -34.45% | -29.36% | -19.67% | 14.11% | 74.34% |
| Gross Profit | -38.23% | -42.72% | -42.47% | -11.60% | 86.67% |
| SG&A Expenses | 4.83% | -0.30% | 6.06% | 11.86% | 30.42% |
| Depreciation & Amortization | -23.88% | -16.63% | -10.99% | 12.94% | 61.71% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -6.63% | -8.63% | -3.15% | 11.00% | 38.70% |
| Operating Income | -20.00% | -18.08% | -24.35% | -16.07% | -15.25% |
| Income Before Tax | -62.98% | -64.66% | -74.31% | -33.55% | -16.38% |
| Income Tax Expenses | 111.98% | 276.92% | 192.14% | 194.16% | 29.46% |
| Earnings from Continuing Operations | -63.07% | -64.94% | -74.51% | -33.80% | -16.40% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -63.07% | -64.94% | -74.51% | -33.80% | -16.40% |
| EBIT | -20.00% | -18.08% | -24.35% | -16.07% | -15.25% |
| EBITDA | -23.36% | -2.43% | -5.86% | 0.83% | -10.03% |
| EPS Basic | 46.94% | 31.02% | 13.49% | 22.88% | 22.70% |
| Normalized Basic EPS | 47.03% | 31.17% | 13.58% | 22.98% | 22.71% |
| EPS Diluted | 46.94% | 31.02% | 13.49% | 22.88% | 22.70% |
| Normalized Diluted EPS | 47.03% | 31.17% | 13.58% | 22.98% | 22.71% |
| Average Basic Shares Outstanding | 492.71% | 325.63% | 102.36% | 71.50% | 50.35% |
| Average Diluted Shares Outstanding | 492.71% | 325.63% | 102.36% | 71.50% | 50.35% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |